Deciphering supportive treatment strategies for toxic epidermal necrolysis.

[en] Toxic epidermal necrolysis (TEN) is a dreadful life-threatening syndrome typically induced by an adverse drug reaction. This condition is characterized by the sudden and extensive destruction of the epidermis. The patient should be promptly addressed to a burn unit where three types of treatment should be administered, namely, (a) specific topical care of the bullous/eroded skin areas, (b) systemic anti-apoptotic/necrotic treatments, and (c) supportive care preventing secondary internal organ failures. This latter aspect is covered by the present review and focuses on (a) early withdrawal of the causative drug, (b) airway management, (c) hydro-electrolytic control, (d) nutritional support, (e) antibiotherapy, (f) prevention of venous thrombosis and gastroduodenal ulcers, and (g) analgesia and anesthesia.

Disciplines :

Dermatology

Author, co-author :

Jennes, Serge; Military Hospital Bruxelles > Burn Unit

PIERARD, Gérald ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Paquet, Philippe

Language :

English

Title :

Deciphering supportive treatment strategies for toxic epidermal necrolysis.

Publication date :

2012

Journal title :

Current Drug Safety

ISSN :

1574-8863

eISSN :

2212-3911

Publisher :

Bentham Science Publishers, United Arab Emirates

Volume :

Issue :

Pages :

361-6

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 01 March 2013

Statistics

Number of views

57 (4 by ULiège)

Number of downloads

1 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Wolf R, Wolf D, Davidovici B. In the pursuit of classifying severe cutaneous adverse reactions. Clin Dermatol 2007; 25: 348-9.
Paquet P, Piérard GE. New insights in toxic epidermal necrolysis (Lyell's syndrome). Clinical considerations, pathobiology and targeted treatments revisited. Drug Saf 2010; 33: 189-212.
Dowlati A, Dowlati Y, Hermanns-Lê T, Piérard GE. Clinical, microscopic and ultrastructural alterations due to mustard gas poisoning. J Eur Acad Dermatol 1992; 1: 199-204.
Firoz BF, Henning JS, Zarzabal LA, et al. Toxic epidermal necrolysis: five years to treatment experience from a burn unit. J Am Acad Dermatol. 2012; 67(4): 630-5.
Paul C, Wolkenstein P, Adle H, et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol 1996; 134: 710-4.
Bachot N, Roujeau JC. Physiopathology and treatment of severe drug eruption. Curr Opin Allergy Clin Immunol 2001; 1: 293-8.
Paquet P, Piérard GE. Toxic epidermal necrolysis: revisiting the tentative link between early apoptosis and late necrosis. Int J Mol Med 2007; 19: 3-10.
Downey A, Jackson C, Harun N, et al. Toxic epidermal necrolysis: review of pathogenesis and management. J Am Acad Dermatol 2012; 66(6): 995-1003.
Paquet P, De Groote D, Piérard GE. Functionally-active macrophage-derived myeloperoxidase in the skin of drug-induced toxic epidermal necrolysis. Dermatology 2010; 220: 201-7.
Tohyama M, Watanabe H, Murakami S, et al. Possible involvement of CD16+ monocyte lineage cells in the epidermal damage of Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol 2012; 166(2): 322-30
Lee MTM, Hung SI, Wie CY, Chen YT. Pharmacogenetics of toxic epidermal necrolysis. Expert Opin Pharmacother 2010; 11: 2153-62.
Niihara H, Kakamu T, Fujita Y, et al. HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population. J Dermatol. 2012 Jul; 39(7): 594-601.
Wu K, Reynolds NJ. Pharamcogenetic screening to prevent carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome: a critical appraisal. Br J Dermatol 2012; 166: 7-11.
Piérard GE, Paquet P. Facing up to toxic epidermal necrolysis. Expert Opin Pharmacother 2010; 11: 2443-6.
Daniel BS, Skowronski G, Myburgh J, et al. Concurrent management of toxic epidermal necrolysis with thermal water spray and non-stick dressings. Acta Dermatovenereol Croat 2012; 20: 210-2.
Palmieri TL, Greenbach DG, Saffle JR, et al. A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil 2002; 23: 87-96.
Schneck J, Fagot JP, Sekula P, et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 2008; 58: 33-40.
Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115: 149-53.
Trent J, Kirsner RS, Romanelli P, Kerdel FA. Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States. Arch Dermatol 2004; 140: 890-2.
Kim KJ, Lee DP, Suh HS, et al. Toxic epidermal necrolysis: analysis of clinical course and SCORTEN-base comparison of mortality rate and treatment modalities in Korean patients. Acta Dermato-Venereol 2005; 85: 497-502.
Guegan S, Bastuji-Garin S, Poszepczynska-Guigné E, et al. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol 2006; 126: 272-6.
Paquet P, Piérard GE, Quatresooz P. Novel treatments for drug-induced toxic epidermal necrolysis (Lyell's syndrome). Int Arch Allergy Immunol 2005; 136, 205-16.
Schnek J, Stat D, Fabot JF, et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study. J Am Acad Dermatol 2008; 58: 33-40.
Bégaud B, Evreux JC, Jouglard J, Lagier G. Unexpected or toxic drug reaction assessment (imputation). Acutalization of the method used in France. Therapie 1984; 40: 111-8.
Moore N, Biour M, Paux G, et al. Adverse drug reaction monitoring: doing it the French way. Lancet 1985; 2: 1056-8.
Piérard-Franchimont C, Quatresooz P, Reginster MA, et al. Finding the drug in cutaneous drug eruptions. Rev Med Liège 2011; 66: 474-7.
Garcia-Doval I, LeCleach L, Bocquet H, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000; 136: 323-7.
Paquet P, Jacob E, Damas P, Piérard GE. Recurrent fatal drug-induced toxic epidermal necrolsis (Lyell's syndrome) after putative P lactam cross-reactivity: case report and scrutinity of antibiotic imputability. Critical Care Med 2002; 30: 2580-3.
Hettiaratchy S, Moloney D, Clarke J. Patients with acute skin loss: are they best managed on a burns unit? Ann Roy Coll Surg 2001; 83: 26-9.
Ellis MW, Oster CN, Turiansky GW, Blanchard JR. A case report and a proposed algorithm for the transfer of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Mil Med 2002; 167; 701-4.
The education committee of the Australian and New Zealand burn association limited. Course manual: Emergency management of severe burns. Aust NZ Burn Ass 1996.
McIvor RA, Zaidi J, Peters WJ, Hyland RH. Acute and chronic respiratory complications of toxic epidermal necrolysis. J Burn Care Rehab 1996; 17; 237-40.
Lebargy F, Wolkenstein P, Gisselbrecht M, et al. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intens Care Med 1997; 13: 1237-44.
Cox Jr CS, Zwischenberger JB, Traber DL, et al. Heparin imrpoves oxygenation and minimizes barotrauma after severe smoke inhalation in the ovine model. Surg Gynecol Obstet 1993; 176; 339-49.
Desa MH, Mlcak R, Richardson J, et al. Reduction in mortality in pediatric patients with inhalation injury with aerosolized heparin/acetylcysteine therapy. J Burn Care Rehab 1998; 19: 210-2.
Roujeau JC, Chosidow O, Saiag P, et al. Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol 1990; 23: 1039-58.
Taylor JA, Grube B, Heimbach DM, et al. Toxic epidermal necrolysis: a comprehensive approach. Clin Pediatr 1989; 28: 404-7.
Paquet P, Piérard GE. Topical treatment options for drug-induced toxic epidermal necrolysis. Expert Opin Pharmacother 2010; 11: 3447-58.
Bhattacharya S, Tripathi HN, Gupta V, et al. Collagen sheet dressings for cutaneous lesions of toxic epidermal necrolysis. Indian J Plast Surg 2011; 44: 474-7.
Coss-Bu JA, Jefferson LS, Levy ML, et al. Nutrition requirements in patients with toxic epidermal necrolysis. Nutr Clin Pract 1997; 12: 81-4.
Windle EM. Immune modulating nutrition support for a patient with severe toxic epidermal necrolysis. J Hum Nutr Diet 2005; 18: 311-4.
Mayes T, Gottschlich M, Khoury J, et al. Energy requirements of pediatric patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Nutr Clin Pract 2008; 23: 547-50.